Fulgent Genetics, Inc.

DB:7F0 Stock Report

Market Cap: €505.3m

Fulgent Genetics Management

Management criteria checks 2/4

Fulgent Genetics' CEO is Ming Hsieh, appointed in May 2016, has a tenure of 8.75 years. total yearly compensation is $5.31M, comprised of 18.8% salary and 81.2% bonuses, including company stock and options. directly owns 28.54% of the company’s shares, worth €144.22M. The average tenure of the management team and the board of directors is 5.9 years and 4 years respectively.

Key information

Ming Hsieh

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage18.8%
CEO tenure8.8yrs
CEO ownership28.5%
Management average tenure5.9yrs
Board average tenure4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ming Hsieh's remuneration changed compared to Fulgent Genetics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$165m

Jun 30 2024n/an/a

-US$163m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$5mUS$1m

-US$168m

Sep 30 2023n/an/a

-US$64m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$5mUS$948k

US$143m

Sep 30 2022n/an/a

US$272m

Jun 30 2022n/an/a

US$392m

Mar 31 2022n/an/a

US$461m

Dec 31 2021US$6mUS$664k

US$507m

Sep 30 2021n/an/a

US$569m

Jun 30 2021n/an/a

US$493m

Mar 31 2021n/an/a

US$417m

Dec 31 2020US$248kUS$240k

US$214m

Sep 30 2020n/an/a

US$48m

Jun 30 2020n/an/a

US$3m

Mar 31 2020n/an/a

-US$459k

Dec 31 2019US$240kUS$240k

-US$411k

Sep 30 2019n/an/a

-US$2m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$240kUS$240k

-US$6m

Compensation vs Market: Ming's total compensation ($USD5.31M) is above average for companies of similar size in the German market ($USD1.00M).

Compensation vs Earnings: Ming's compensation has increased whilst the company is unprofitable.

CEO

Ming Hsieh (68 yo)

8.8yrs

Tenure

US$5,309,167

Compensation

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...

Leadership Team

NamePositionTenureCompensationOwnership
Ming Hsieh
Chairman & CEO8.8yrsUS$5.31m28.54%
€ 144.2m
Jian Xie
COO & President6.8yrsUS$1.79m1.47%
€ 7.4m
Paul Kim
Chief Financial Officer9.1yrsUS$1.78m0.41%
€ 2.1m
Hanlin Gao
Chief Scientific Officer & Lab Director9.1yrsUS$1.49m2.8%
€ 14.2m
Natalie Prescott
General Counsel & Chief Privacy Officer2.8yrsno datano data
Doreen Ng
Vice President of Operations & Compliance4.3yrsno datano data
Jakub Sram
Vice President of Business Development & Sales10.1yrsno datano data
Ellen Tsui
Vice President of Human Resources2.8yrsno datano data
Brandon Perthuis
Chief Commercial Officer4.9yrsno datano data
Ray Yin
President & Chief Scientific Officer of Fulgent Pharma2.3yrsno datano data

5.9yrs

Average Tenure

57.5yo

Average Age

Experienced Management: 7F0's management team is seasoned and experienced (5.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ming Hsieh
Chairman & CEO8.8yrsUS$5.31m28.54%
€ 144.2m
Regina Groves
Independent Non-Employee Director2.1yrsUS$625.60k0.0039%
€ 19.6k
Linda Marsh
Independent Director5.5yrsUS$270.50k0.061%
€ 308.2k
Michael Nohaile
Independent Non-Employee Director2.5yrsUS$268.50k0.0078%
€ 39.4k

4.0yrs

Average Tenure

67yo

Average Age

Experienced Board: 7F0's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/20 18:11
End of Day Share Price 2025/02/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fulgent Genetics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Karen KoskiBTIG
Andrew CooperCGS International
Erin Wilson WrightCredit Suisse